Ann: Major Biopharmaceutical Signs to Patient Engagement Program-MDR.AX, page-19

The only thing missing in any of the great announcements that have been coming out is indicative revenues. This means, depending on whether, as an investor, you view the stock based on balance sheet (revenue $) or qualitative metrics (# of pharmacies, sign-ups etc) you will still have some desire to see "runs on the board" before committing. Some may in fact be waiting for the 4C at the end of July, to analyse the cashburn (given the new appointments) versus revenue from the increase in pharmacies and also the pharmaceutical company sign-ups.

imo MDR is still best judged on qualitative metrics, as they are very much setting the stage for large future revenue to hit the bottom line, if successfully executed. Of course, the quicker they get to +ocf the better it will be and reduce the risk of future dilution (or at least the quantity of dilution)